Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 10;16(1):211.
doi: 10.1186/s13023-021-01828-y.

The impact of severe rare chronic neurological disease in childhood on the quality of life of families-a study on MLD and PCH2

Affiliations

The impact of severe rare chronic neurological disease in childhood on the quality of life of families-a study on MLD and PCH2

Louisa Ammann-Schnell et al. Orphanet J Rare Dis. .

Abstract

Background: Rare and severe neurological disorders in childhood not only heavily affect the life perspective of the patients, but also their caregivers and families. The aim of this study was to investigate the impact of such diseases on the family, especially on the quality of life and life perspectives of parents, but also on the families' everyday life, based on the model of two diseases which have been well described in recent years with respect to symptoms and course: metachromatic leukodystrophy (MLD) and pontocerebellar hypoplasia type 2 (PCH2). PCH2 is a primary severe developmental disorder, while children with MLD initially develop normally and then progressively deteriorate.

Methods: Using a semi-standardized questionnaire, 43 families with children suffering from MLD (n = 30) or PCH2 (n = 19) reported data on the severity of the illness/symptoms, on family support and the care situation, as well as on the circumstances of non-affected siblings and the parents' work situation. In addition, the quality of life of parents and general family functioning was assessed using the PedsQL™ Family Impact Module [23]. Results for the latter were compared to published data from families with children without any chronic condition using student's t-tests for independent samples. Potential factors influencing the PedsQL™ scores were analyzed using Spearman's rank correlation.

Results: Parents of children with MLD and PCH2 reported significantly lower health-related quality of life (HRQOL) compared to parents of healthy children (P < 0.001). Mothers showed significantly poorer HRQOL (P < 0.05) and were significantly more dissatisfied with their professional development (P < 0.05) than fathers, and this was seen in relation to their child's disease. Neither the form of disease ('primary' symptomatic PCH2 or 'secondary' symptomatic MLD), nor the severity of the child's illness (in terms of gross motor and speech function) had a specific impact on HRQOL in families. However, the time from diagnosis and advanced symptoms in the terminal disease stage were experienced as especially distressing.

Conclusions: This study illustrates that MLD and PCH2 affect mothers in particular, but also the entire family. This underlines the need for personalized care and counselling of parents and families, especially following diagnosis and during the end stage in a child with a severe, rare chronic neurological disorder.

Keywords: Disease burden; Metachromatic leukodystrophy; Parents; Pontocerebellar hypoplasia type 2; Quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

SG received institutional research support from Shire plc, outside of the submitted work. He is advisor and co-investigator for trials in Metachromatic Leukodystrophy (Shire/Takeda, Orchard, Homology Medicine), but receives no personal payment related to this role.

Figures

Fig. 1
Fig. 1
PedsQL™ Family Impact Module. Higher values equal better functioning/less negative impact. *P value is significant at < 0.05 level; **Medrano et al. [26]. Comparison between individual samples, as well as between individual samples and the ‘no chronic condition’ sample. PedsQL™, Pediatric Quality of Life Inventory [23]. MLD, metachromatic leukodystrophy. PCH2, pontocerebellar hypoplasia type 2. HRQOL, health-related quality of life
Fig. 2
Fig. 2
Influence of parents’ time after diagnosis on Quality of Life measures. Higher values equal better functioning/less negative impact. *P value is significant at < 0.05 level. Comparison between “more distressing” and “less distressing” samples. HRQOL, health-related quality of life
Fig. 3
Fig. 3
Comparison of HRQOL between mothers and fathers. Higher values equal better functioning/less negative impact. *P value is significant at < 0.05 level; **P value is significant at < 0.01 level. ***Medrano et al. [26]. Comparison between individual samples, as well as between individual samples and the ‘no chronic condition’ sample. MLD, metachromatic leukodystrophy. PCH2, pontocerebellar hypoplasia type 2. HRQOL, health-related quality of life. Chr., chronic
Fig. 4
Fig. 4
Satisfaction of parents with their professional development. Higher values equal better satisfaction with professional development. *P value is significant at < 0.05 level. Comparison between mothers and fathers. MLD, metachromatic leukodystrophy. PCH2, pontocerebellar hypoplasia type 2

References

    1. Malcolm C, Forbat L, Anderson G, Gibson F, Hain R. Challenging symptom profiles of life-limiting conditions in children: a survey of care professionals and families. Palliat Med. 2011;25:357–364. doi: 10.1177/0269216310391346. - DOI - PubMed
    1. Malcolm C, Hain R, Gibson F, Adams S, Anderson G, Forbat L. Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families: Challenging symptoms in rare LLCs. Acta Paediatr. 2012;101:985–992. doi: 10.1111/j.1651-2227.2012.02680.x. - DOI - PubMed
    1. Eichler FS, Cox TM, Crombez E, Dali CÍ, Kohlschütter A. Metachromatic Leukodystrophy: An Assessment of Disease Burden. J Child Neurol. 2016;31:1457–1463. doi: 10.1177/0883073816656401. - DOI - PubMed
    1. Conijn T, Nijmeijer SCM, van Oers HA, Wijburg FA, Haverman L. Psychosocial Functioning in Parents of MPS III Patients. JIMD Rep. 2019;44:33–41. doi: 10.1007/8904_2018_119. - DOI - PMC - PubMed
    1. Gainotti S, Mascalzoni D, Bros-Facer V, Petrini C, Floridia G, Roos M, et al. Meeting patients’ right to the correct diagnosis: ongoing international initiatives on undiagnosed rare diseases and ethical and social issues. Int J Environ Res Public Health [Internet]. 2018 [cited 2021 Feb 7];15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210164/. - PMC - PubMed

Publication types

Supplementary concepts